Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
4,507
Views
2
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada

Fred Saada Department of Urology, University of Montreal Hospital Center, Montreal, QC, CanadaCorrespondence[email protected]
,
Andrew Chilellib HEOR Oncology, Astellas Pharma, Markham, ON, Canada
,
Benny Huib HEOR Oncology, Astellas Pharma, Markham, ON, Canada
,
Sergey Muratovc IQVIA, Kirkland, QC, Canada;d Department of Health Research Methods, Evidence, and Impact, McMaster University, Faculty of Health Sciences, Hamilton, ON, Canada
,
Arijit Gangulie HEOR Oncology, Astellas Pharma Inc, Northbrook, USA
,
Scott Northf Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
&
Bobby Shayegang St. Joseph’s Healthcare, McMaster University, Institute of Urology, Hamilton, ON, Canada
 show all
Pages 583-590 | Received 14 Jan 2022, Accepted 13 Apr 2022, Published online: 13 May 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.